Preclinical study reveals enhanced amyloid-beta clearance through PIEZO1 activation in Alzheimer's disease models, suggesting a novel therapeutic paradigm.
These results indicate that the compromised function of microglia in AD could be improved by controlled activation of PIEZO1 channels resulting in alleviated Aβ burden. Pharmacological regulation of these mechanoreceptors in microglia could represent a novel therapeutic paradigm for AD.
No takes yet. Share an insight, caveat, or question.
Jäntti et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: